Journal: Immunity

Article Title: The SPPL3-Defined Glycosphingolipid Repertoire Orchestrates HLA Class I-Mediated Immune Responses

doi: 10.1016/j.immuni.2020.11.003

Figure Lengend Snippet: KEY RESOURCES TABLE

Article Snippet: To release the glycans from the GSLs, a mixture of 2 μL Endoglycoceramidase I (EGCase I recombinant clone derived from Rhodococcus triatomea and expressed in Escherichia coli (12mU, NEB)), 4 μL 10x EGCase I buffer (500mM HEPES, 1M NaCl, 20mM DTT and 0.1% Brij 35, pH5.2, NEB) and 34 μL water (pH5.2) was added to each sample and incubated for 16h at 37°C.

Techniques: Recombinant, Derivative Assay, Enzyme-linked Immunosorbent Assay, Sequencing, CRISPR, Plasmid Preparation, Expressing, Software, Single-cell Analysis

Journal: Molecules

Article Title: Activity of Amphotericin B-Loaded Chitosan Nanoparticles against Experimental Cutaneous Leishmaniasis

doi: 10.3390/molecules25174002

Figure Lengend Snippet: Figure 2. AmB nanoparticles efficacy in the lesion cure model in BALB/c mice infected with luciferase-expressing L. major parasites. L. major infected mice were allocated into 8 groups: (G1) represents untreated infected group, (G2) paromomycin as a positive control (50 mg/kg/QD for 10 days; i.p.), (G3) AmBisome® as a comparison group (10 mg/kg/QAD for 10 days; i.v.), (G4) CH-TPP nanoparticles (mass of nanoparticles in the blank formulations reflected the related AmB-loaded ones) (QAD for 10 days; i.v.), (G5) AmB-CH-TPP nanoparticles (5 mg of AmB/kg/QAD for 10 days; i.v.), (G6) CH-Dex nanoparticles (mass of nanoparticles in the blank formulations reflected the related AmB-loaded ones) (QAD for 10 days; iv), (G7) AmB-CH-Dex nanoparticles (10 mg of AmB/kg/one dose; i.v.), 24 h after the first (and only) dose of the formulation, the mice looked unwell with piloerection and weight loss, therefore data of G7 are not represented in the figure or (G8) the nanoparticles vehicle (distilled water, QAD for 10 days; i.v.). QAD: every other day, QD: once a day. The average lesion size and parasite load represent the mean ± SD. One way-ANOVA for parasite load (bioluminescence signal), parasite load (qPCR) and repeated measures for lesion size followed by Tukey’s multiple-comparison tests was used to compare outcomes among the groups. A p-value < 0.05 was considered statistically significant ((*) p < 0.05, (**) p > 0.05 and (***) p < 0.05). (A) represents mean lesion size progression in function of time since the start of treatment, (B) represents the % reduction in lesion size compared with G1 (untreated infected group) at day 10, (C) represents the bioluminescence signal in function of time since the start of treatment, (D) represents the bioluminescence signal compared with G1 (untreated infected group) at day 10, (E) represents the parasite load (qPCR-DNA) at day 10 and (F) represents the % reduction in the parasite load (qPCR) compared with G1 (untreated infected group) at day 10.

Article Snippet: Such reductions were statistically similar to those caused by the positive control paromomycin (50 mg/kg/QD for 10 days; i.p., p > 0.05 by one-way-ANOVA-post Tukey) but significantly greater (around 2×) than those caused by AmBisome® (10 mg of AmB/kg/QAD for 10 days; i.v., p < 0.05 by one-way-ANOVA-post Tukey) (Figure 2).

Techniques: Infection, Luciferase, Expressing, Positive Control, Comparison, Formulation

Journal: Molecules

Article Title: Activity of Amphotericin B-Loaded Chitosan Nanoparticles against Experimental Cutaneous Leishmaniasis

doi: 10.3390/molecules25174002

Figure Lengend Snippet: Figure 4. AmB nanoparticles efficacy in the lesion cure model in BALB/c mice infected with luciferase-expressing L. major parasites. L. major infected mice were allocated into 7 groups: (G1) represents untreated infected group, (G2) paromomycin as a positive control (50 mg/kg/QD for 10 days; i.p.), (G3) AmBisome® as a comparison group (10 mg/kg/QAD for 10 days; i.v.), (G4) AmB-CH-TPP nanoparticles (5 mg of AmB/kg/QAD for 10 days; i.v.), (G5) AmB-CH-TPP nanoparticles (2.5 mg of AmB/kg/QAD for 10 days; i.v.), (G6) AmB-CH-TPP nanoparticles (1.25 mg of AmB/kg/QAD for 10 days; i.v.) and (G7) CH-TPP nanoparticles (nanoparticles mass being equivalent to that in animals receiving the 5 mg/kg dose) (QAD for 10 days; i.v.). The average lesion size and parasite load represent the mean ± SD. One-way-ANOVA for parasite load (bioluminescence signal), parasite load (qPCR) and repeated measures for lesion size followed by Tukey’s multiple-comparison tests was used to compare outcomes among the groups. A p-value < 0.05 was considered statistically significant ((*) p < 0.05, (**) p > 0.05, (***) p < 0.05 and (****) p > 0.05). (A) represents mean lesion size progression in function of time since the start of treatment, (B) represents the % reduction in lesion size compared with G1 (untreated infected group) at day 10, (C) represents the bioluminescence signal in function of time since the start of treatment, (D) represents the bioluminescence signal compared with G1 (untreated infected group) at day 10, (E) represents the parasite load (qPCR-DNA) at day 10 and (F) represents the % reduction in the parasite load (qPCR) compared with G1 (untreated infected group) at day 10.

Article Snippet: Such reductions were statistically similar to those caused by the positive control paromomycin (50 mg/kg/QD for 10 days; i.p., p > 0.05 by one-way-ANOVA-post Tukey) but significantly greater (around 2×) than those caused by AmBisome® (10 mg of AmB/kg/QAD for 10 days; i.v., p < 0.05 by one-way-ANOVA-post Tukey) (Figure 2).

Techniques: Infection, Luciferase, Expressing, Positive Control, Comparison